Windisch M - Search Results

1

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Windisch M, Hutter-Paier B, Schreiner E, Wronski R. Windisch M, et al. J Mol Neurosci. 2004;24(1):155-65. doi: 10.1385/JMN:24:1:155. J Mol Neurosci. 2004. PMID: 15314265

2

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Wronski R. Windisch M, et al. Curr Alzheimer Res. 2007 Dec;4(5):556-61. doi: 10.2174/156720507783018343. Curr Alzheimer Res. 2007. PMID: 18220522 Review.

3

Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins.

Schwach G, Tschemmernegg M, Pfragner R, Ingolic E, Schreiner E, Windisch M. Schwach G, et al. Among authors: windisch m. J Mol Neurosci. 2010 May;41(1):80-8. doi: 10.1007/s12031-009-9289-1. Epub 2009 Oct 9. J Mol Neurosci. 2010. PMID: 19816809

4

Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line.

Czvitkovich S, Duller S, Mathiesen E, Lorenzoni K, Imbimbo BP, Hutter-Paier B, Windisch M, Wronski R. Czvitkovich S, et al. Among authors: windisch m. J Mol Neurosci. 2011 Mar;43(3):257-67. doi: 10.1007/s12031-010-9416-z. Epub 2010 Jul 6. J Mol Neurosci. 2011. PMID: 20603724 Free PMC article.

5

Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Windisch M, et al. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9. doi: 10.1007/s12031-002-0012-8. J Mol Neurosci. 2002. PMID: 12212795

6

The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition.

Windisch M, Hutter-Paier B, Jerkovic L, Imbimbo B, Villetti G. Windisch M, et al. Neurosci Lett. 2003 May 8;341(3):181-4. doi: 10.1016/s0304-3940(03)00125-3. Neurosci Lett. 2003. PMID: 12697278

7

Current drugs and future hopes in the treatment of Alzheimer's disease.

Windisch M, Hutter-Paier B, Schreiner E. Windisch M, et al. J Neural Transm Suppl. 2002;(62):149-64. doi: 10.1007/978-3-7091-6139-5_15. J Neural Transm Suppl. 2002. PMID: 12456060 Review.

8

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R. Windisch M, et al. Curr Alzheimer Res. 2007 Sep;4(4):446-57. doi: 10.2174/156720507781788783. Curr Alzheimer Res. 2007. PMID: 17908049 Review.

9

The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?

Windisch M, Wolf H, Hutter-Paier B, Wronski R. Windisch M, et al. Neurodegener Dis. 2008;5(3-4):218-21. doi: 10.1159/000113707. Epub 2008 Mar 6. Neurodegener Dis. 2008. PMID: 18322395 Review.

10

The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.

Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. Hutter-Paier B, et al. Among authors: windisch m. Neuron. 2004 Oct 14;44(2):227-38. doi: 10.1016/j.neuron.2004.08.043. Neuron. 2004. PMID: 15473963 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters